CLASS ACTION UPDATE for DOX, RMO and FREQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Back to Newsroom
Mentioned in this Article

CLASS ACTION UPDATE for DOX, RMO and FREQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Monday, June 7, 2021 5:40 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / June 7, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

DOX Shareholders Click Here: https://www.zlk.com/pslra-1/amdocs-limited-loss-submission-form?prid=16608&wire=1
RMO Shareholders Click Here: https://www.zlk.com/pslra-1/romeo-power-inc-loss-submission-form?prid=16608&wire=1
FREQ Shareholders Click Here: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16608&wire=1
 

* ADDITIONAL INFORMATION BELOW *

Amdocs Limited (NASDAQ:DOX)

DOX Lawsuit on behalf of: investors who purchased December 13, 2016 - March 30, 2021
Lead Plaintiff Deadline : June 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/amdocs-limited-loss-submission-form?prid=16608&wire=1

According to the filed complaint, during the class period, Amdocs Limited made materially false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Romeo Power, Inc. (NYSE:RMO)

RMO Lawsuit on behalf of: investors who purchased October 5, 2020 - March 30, 2021
Lead Plaintiff Deadline : June 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/romeo-power-inc-loss-submission-form?prid=16608&wire=1

According to the filed complaint, during the class period, Romeo Power, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Romeo had only two battery cell suppliers, not four, (ii) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and business prospects, (iii) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (iv) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (v) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. Given the supply constraint that Romeo was experiencing during the Class Period, Defendants had no reasonable basis to represent that the Company had the ability to meet customer demand and that it would support growth in revenue in 2021.

Frequency Therapeutics, Inc. (NASDAQ:FREQ)

FREQ Lawsuit on behalf of: investors who purchased November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline : August 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16608&wire=1

According to the filed complaint, during the class period, Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions